equityflowunderstand the flow and follow it

EquityFlow › Companies › Precirix

Precirix

Biotech · Brussels, BE

Belgian biotech developing radio-immunotherapeutic drugs for cancer.

Founders

Tony Lahoutte (Belgium · ♂) — As head of VUB's Molecular Imaging group and UZ Brussel's nuclear medicine department, he spun out Precirix to turn camelid antibody research into precision radiopharmaceuticals.
Matthias D'Huyvetter (Belgium · ♂) — A VUB researcher in radiolabelled single-domain antibodies, he co-founded Precirix to develop targeted radiotherapy against cancer.
Jens De Vos (Belgium · ♂) — Coming from VUB's molecular imaging research, he co-founded Precirix to commercialize camelid-antibody radiopharmaceuticals.

In the network

Shares the most investors with (number = shared investors):

NMD Pharma 3 Adcendo 2 CatalYm 2 Complement Therapeutics 2 Hemab Therapeutics 2 Noema Pharma 2 Onward 2 Orbis Medicines 2 SynOx Therapeutics 2

Funding history

Date	Round	Amount
Apr 2022	Series B Brussels radiopharmaceutical biotech Precirix raised an 80M euro Series B co-led by INKEF Capital, Jeito Capital and Forbion.	$80M

Investors

Tap an investor to see what else they have backed.

Forbion GIMV HealthCap INKEF Capital Jeito Capital Novo Holdings

Other companies in Biotech

Imperagen Haga Bioscience Pixelgen Technologies Gallant Chai Discovery SNIPR Biome Cellbox Labs Scope Biosciences GenLumina Actithera NUCLIDIUM Anocca

Other companies in BE

TurnUp Companion.energy Sensie D-CRBN Borro EDGX Koios Care Bizzy The Hacking Games Cowboy BetterPic Axiles Bionics

Other companies at Series B stage

0x Labs 11x.ai 1K Kirana 1X Technologies 1plusX 3Commas 3SC 4baseCare 4screen 8fig 9fin ACALL

Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.